ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
sPDGFRβ and neuroinflammation are associated with AD biomarkers and differ by race: The ASCEND Study.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Elevated levels of circulating plasma sPDGFRβ in cognitively impaired APOE4 carriers.GeroScience · 2026Article
- Associations between parental history of dementia and plasma markers of inflammation in a multi-ethnic middle-aged community of adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Neurovascular dysfunction in the development and progression of neuroinflammatory diseases.Frontiers in cellular neuroscience · 2026Review
- CSF estrogens' relationships to neuroinflammatory markers and brain networks in middle-aged and older black and white women.Journal of neuroinflammation · 2025Article
- Biomarkers of blood-brain barrier and neurovascular unit integrity in human cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Vascular and metabolic responses to elevated circulating PDGF-BB in mice: A multiparametric MRI study.Health and metabolism · 2025Article
- Hitting the (bio)mark part 1: selecting and measuring biomarkers in cardiovascular research.European journal of cardiovascular nursing · 2024Review
- Neuroimaging correlates of Alzheimer's disease biomarker concentrations in a racially diverse high-risk cohort of middle-aged adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Terminally differentiated effector memory T cells associate with cognitive and AD-related biomarkers in an aging-based community cohort.Immunity & ageing : I & A · 2024Article
- sPDGFRβ and neuroinflammation are associated with AD biomarkers and differ by race: The ASCEND Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Serum detection of blood brain barrier injury in subjects with a history of stroke and transient ischemic attack.JVS-vascular science · 2024Article
- Population disparities in Alzheimer's disease: A systematic review of fluid and neuroimaging biomarkers.Alzheimer's & dementia (Amsterdam, Netherlands)Review
- Pilot: Salivary lactoferrin as a potential preclinical Alzheimer's disease biomarker.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
introductionThere remains an urgent need to identify preclinical pathophysiological mechanisms of Alzheimer's disease (AD) development in high-risk, racially diverse populations. We explored the relationship between cerebrospinal fluid (CSF) markers of vascular injury and neuroinflammation with AD biomarkers in middle-aged Black/African American (B/AA) and non-Hispanic White (NHW) participants.
methodsAdults (45-65 years) with a parental history of AD were enrolled (n = 82). CSF and blood biomarkers were collected at baseline and year 2.
resultsCSF total tau (t-tau), phosphorylated tau (p-tau), and amyloid beta (Aβ)40 were elevated at year 2 compared to baseline. CSF soluble platelet-derived growth factor receptor β (sPDGFRβ) levels, a marker of pericyte injury, correlated positively with t-tau, p-tau, Aβ40 markers of vascular injury, and cytokines at baseline and year 2. CSF sPDGFRβ and tau were significantly lower in B/AA than NHW. DISCUSSION: Vascular dysfunction and neuroinflammation may precede cognitive decline and disease pathology in the very early preclinical stages of AD, and there are race-related differences in these relationships. HIGHLIGHTS: Cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers changed over 2 years in high-risk middle-aged adults. Markers of vascular dysfunction were associated with the CSF biomarkers amyloid beta and tau. AD biomarkers were lower in Black compared to non-Hispanic White individuals. Markers of vascular dysfunction were lower among Black individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.